Department of Psychiatry, Division of Geriatric Psychiatry, University Hospital Geneva, Geneva, Switzerland.
VIVACY Laboratories, Archamps Technopole, Archamps, France.
Neural Plast. 2022 Feb 21;2022:3172861. doi: 10.1155/2022/3172861. eCollection 2022.
Recently, we showed that DNA double-strand breaks (DSBs) are increased by the A -amyloid peptide and decreased by all-trans retinoic acid (RA) in SH-SY5Y cells and C57BL/6J mice. The present work was aimed at investigating DSBs in cells and murine models of Alzheimer's disease carrying the mutation. We observed that DSBs could hardly decrease following RA treatment in the mutated cells compared to the wild-type cells. The activation of the amyloidogenic pathway is proposed in the former case as A - and RA-dependent DSBs changes were reproduced by an -secretase and a -secretase inhibitions, respectively. Unexpectedly, the cells showed lower DSB levels than the controls. As the DSB repair proteins Tip60 and Fe65 were less expressed in the mutated cell nuclei, they do not appear to contribute to this difference. On the contrary, full-length BRCA1 and BARD1 proteins were significantly increased in the chromatin compartment of the mutated cells, suggesting that they decrease DSBs in the pathological situation. These Western blot data were corroborated by in situ proximity ligation assays: the numbers of BRCA1-BARD1, not of Fe65-Tip60 heterodimers, were increased only in the mutated cell nuclei. RA also enhanced the expression of BARD1 and of the 90 kDa BRCA1 isoform. The increased BRCA1 expression in the mutated cells can be related to the enhanced difficulty to inhibit this pathway by BRCA1 siRNA in these cells. Overall, our study suggests that at earlier stages of the disease, similarly to PS1 P117L cells, a compensatory mechanism exists that decreases DSB levels via an activation of the BRCA1/BARD1 pathway. This supports the importance of this pathway in neuroprotection against Alzheimer's disease.
最近,我们发现 A -淀粉样肽会增加 SH-SY5Y 细胞和 C57BL/6J 小鼠中的 DNA 双链断裂(DSB),而全反式视黄酸(RA)则会减少 DSB。本研究旨在探讨携带突变的阿尔茨海默病细胞和小鼠模型中的 DSB。我们观察到,与野生型细胞相比,突变细胞中的 DSB 在 RA 处理后几乎没有减少。在前者情况下,淀粉样蛋白形成途径的激活被提出,因为 A -和 RA 依赖性 DSB 变化分别被 -分泌酶和 -分泌酶抑制剂所复制。出乎意料的是,突变细胞的 DSB 水平低于对照细胞。由于 Tip60 和 Fe65 等 DSB 修复蛋白在突变细胞核中的表达较少,它们似乎不会导致这种差异。相反,全长 BRCA1 和 BARD1 蛋白在突变细胞的染色质区室中显著增加,表明它们在病理情况下减少 DSB。这些 Western blot 数据得到了原位邻近连接分析的证实:仅在突变细胞核中,BRCA1-BARD1 而不是 Fe65-Tip60 异二聚体的数量增加。RA 还增强了 BARD1 和 90 kDa BRCA1 同工型的表达。突变细胞中 BRCA1 表达的增加可能与 BRCA1 siRNA 更难以抑制该途径有关。总体而言,我们的研究表明,在疾病的早期阶段,类似于 PS1 P117L 细胞,存在一种代偿机制,通过激活 BRCA1/BARD1 途径降低 DSB 水平。这支持了该途径在阿尔茨海默病神经保护中的重要性。